BIOMARKERS OF RESPONSE TO COMBINATION CABOZANTINIB + NIVOLUMAV IN ADVANCED RENAL CELL CARCINOMA

$667,500FY2022Department of the ArmyDOD

Dana-Farber Cancer Institute, Inc.

Investigators